今年一级市场回暖，有投资人看到新“光线”

Core Insights - The investment landscape in China's primary market has significantly improved in 2025, with a notable recovery in IPO activities and mergers and acquisitions, indicating a departure from the previous "winter" phase of the industry [1][3][4] Group 1: Market Recovery - In 2025, A-share IPOs have seen 111 new listings, raising approximately 125.3 billion yuan, while Hong Kong's IPOs reached 111 companies with a net fundraising of about 243.7 billion HKD [4] - VC/PE-backed IPOs for Chinese companies totaled 102 in the first three quarters, involving 562 institutions, marking a 27.4% year-on-year increase in the number of institutions benefiting from IPOs [4] - The overall investment environment has shifted positively, with fundraising, investment, and exit activities all showing signs of recovery [1][3] Group 2: Policy Support - Recent policy initiatives, including the launch of the National Venture Capital Guidance Fund with a 20-year lifespan, are designed to enhance the investment climate and support long-term capital [1][8] - The introduction of various supportive measures for venture and equity investments, such as the "17 Measures for Venture Capital," has provided new directions for the market [4][8] Group 3: Challenges in the Market - Despite the recovery, challenges remain, particularly for small and medium-sized General Partners (GPs), who face difficulties in fundraising, with over 80% of new registrations concentrated among leading institutions and state-owned platforms [6][7] - There is a growing trend where Limited Partners (LPs) prefer to invest only in state-owned GPs, which exacerbates the fundraising challenges for private GPs [6][7] Group 4: Future Investment Focus - The investment focus is shifting towards hard technology sectors such as information technology, semiconductors, and biomedicine, with a strategic emphasis on key links within the industrial chain rather than solely on star companies [5][6] - The upcoming "14th Five-Year Plan" period is expected to prioritize the development of patient capital and enhance risk management and incentive mechanisms [4][8]